000950 重藥控股
按盤價 
6.170 -0.280 (-4.341%)
6.170 -0.280 (-4.341%) | 2025/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 62,211,402 | 4.22% | 80,561,532 | 78,397,354 | 67,829,010 | 62,520,755 | |
| 減：營業總成本 | 61,116,440 | 3.48% | 79,839,412 | 77,352,038 | 66,608,402 | 61,148,245 | |
| 其中:營業成本 | 57,722,565 | 4.47% | 74,572,958 | 72,130,851 | 62,008,780 | 56,782,329 | |
| 財務費用 | 557,907 | -31.45% | 1,084,281 | 1,302,028 | 1,094,235 | 1,087,649 | |
| 資產減值損失 | (19,865) | 102.94% | (89,975) | (27,756) | (39,943) | (12,883) | |
| 公允價值變動收益 | (861) | -112.22% | 6,919 | 16,162 | 2,318 | 126,883 | |
| 投資收益 | 139,992 | -42.13% | 402,412 | 301,548 | 293,349 | 302,690 | |
| 其中：對聯營企業和合營企業的投資收益 | 224,461 | -7.89% | 396,688 | 291,454 | 286,195 | 279,408 | |
| 營業利潤 | 665,171 | 21.37% | 562,641 | 964,883 | 1,435,011 | 1,560,927 | |
| 利潤總額 | 657,436 | 20.17% | 557,508 | 966,329 | 1,472,490 | 1,580,286 | |
| 減：所得稅費用 | 125,058 | -10.82% | 155,717 | 236,042 | 309,496 | 289,613 | |
| 淨利潤 | 532,378 | 30.86% | 401,791 | 730,288 | 1,162,995 | 1,290,673 | |
| 減：非控股權益 | 148,367 | 29.45% | 118,798 | 105,654 | 210,719 | 285,229 | |
| 股東淨利潤 | 384,010 | 31.41% | 282,994 | 624,633 | 952,276 | 1,005,444 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.220 | 29.41% | 0.160 | 0.360 | 0.550 | 0.580 | |
| 每股派息 (元) * | 0.030 | 0.00% | 0.060 | 0.050 | 0.060 | 0.105 | |
| 每股淨資產 (元) * | 6.687 | 1.05% | 6.554 | 6.507 | 6.110 | 5.633 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 12/12/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
